Background
Methodology
Searches
Eligibility of studies
Study selection
Data extraction
Levels of evidence and quality assessment
Results
Study | Duration of Study | Group Intervention and Comparators | n | Condition | Sex No. (%) | Age (mean ± SD) | Mass (mean kg ± SD) | Height (mean m ± SD) | BMI (mean kg/m2 ± SD) | Outcomes |
---|---|---|---|---|---|---|---|---|---|---|
Corrective Therapeutic Footwear | ||||||||||
Chen et al. (2015) [16] | 44 months | Group 1 CTF and DB | 20 | Group 1 to 3 CTEV (not stated if idiopathic) DiMeglio score ≤Moderate | ♂12 (60) | 4.9 yrs. ±1.1a | 19.2 | 1.10 | Not reported | Skeletal geometry (3D laser scanning) |
♀ 8 (40) | 3.6 | 0.11 | ||||||||
Biomechanical (plantar pressure) | ||||||||||
Group2 DB and Own footwear | 15 | ♂9 (60) | 4.7 yrs. ±0.7a | 17.7 | 1.06 | |||||
♀ 6 (40) | 2.5 | 0.74 | ||||||||
Group 3 FAS and CTF | 18 | ♂8 (44) | 4.9 yrs. ±1a | 19.3 | 1.10 | |||||
♀10 (56) | 3.8 | 0.11 | ||||||||
Kanatali et al. (2016) | mean 34.6 ± 10.9 months | Group 1 CTF | 21 | Flexible pes planus asymptomatic, | ♂33 (73) | 41.6 monthsc | Not reported | Not reported | Not reported | Skeletal geometry (radiographic) |
Group 2 Own footwear | 24 | ♀12 (27) b | 36 monthsc | |||||||
Wenger et al. (1989) [37] | 3 years | Group 1 CTF | 28d | Flexible pes planus | ♂16 (57) | 32.2 months ±17c | Not reported | Not reported | Not reported | Skeletal geometry (radiographic) |
♀12 (43) | ||||||||||
Group 2 SLF | 21d | 13 (62) | 27.2 months ±11.6c | |||||||
♀8 (38) | ||||||||||
Group 3 CTF with Helfet Heel Cup | 27d | ♂22 (81) | 28.7 months ±13.5c | |||||||
♀5 (19) | ||||||||||
Group 4 SLF with UCBL | 22d | 9 (41) | 28.2 months ±10.7c | |||||||
♀13 (59) | ||||||||||
Functional Therapeutic Footwear | ||||||||||
Functional Stability | ||||||||||
Abd Elkader et al. (2013) [14] | Within 1 day | Group 1 BF, FSTF | 15 | Down's syndrome with flexible pes planus | ♂11 (36) | 3.67 yrs. ±0.72 | 16.46 | 1.01 0.069 | 16.01 | Biomechanical (spatiotemporal) |
♀14 (47) b,e | 2.74 | 1.67 | ||||||||
Group 2 BF, Foot Taping | 15 | 4.06 yrs. 0.88 | 15.61 | 0.99 0.032 | 15.49 | |||||
1.99 | 1.47 | |||||||||
Aboutorabi et al. (2014) [11] | Within 1 day | Group 1 BF, FSTF, SLS with FO | 30 | Flexible pes planus | ♂18 (67) | 7.87 yrs. ±1.45 | 31.4 | 123.06 10.25 | 20.2 | Biomechanical (spatiotemporal) |
♀12 (33) | 5.74 | 1.58 | ||||||||
Group 2, BF, FSTF, SLS with FO | 20 | Control, typically developing | ♂12 (60) | 7.8 yrs. ±1.31 | 32.81 | 1.28 | 19.87 | |||
♀8 (40) | 6.66 | .11 | 1.4 | |||||||
Bakker et al. (1997) [38] | 16 Months | Group 1 FSTF | 7 | Duchenne muscular dystrophy | ♂48 (100) | Age range 5 to 12f | Not reported | Not reported | Not reported | Secondary outcomes |
Group 2 AFO | 20 | |||||||||
Group 3 SF | 6 | |||||||||
Group 4 KAFO | 5 | |||||||||
Group 5 Own footwear | 41 | |||||||||
Basta et al (1977) [39] | 4 years | Group, 1, BF, FSTF, FSTF with CNP | 10 | Symptomatic flexible pes planus | Not reported | Age Range 6.5 to 7 yearsf | Not reported | Not reported | Not reported | Skeletal geometry (radiographic) |
Group 2, BF, FSTF, FSTF with CNP, | 10 | |||||||||
Group 3, BF, FSTF, FSTF with CNP, FSTF with PCNP, | 10 | |||||||||
Group 4, BF, S, SLF with HB, SLF with CNP, FSTFWS | 6 | |||||||||
Group 5 and 6 formed from groups 1 to 4, Four participants lost to follow up. | ||||||||||
Group 5, BF, FSTF, FSTF with CNP Group | 16 | |||||||||
6, BF, CNP, with Own footwear | 16 | |||||||||
Group 7, BF, FSTF, FSTF with CNP, | 14 | |||||||||
Jagadamma et al (2009) [40] | Within 1 day | One group AFO and SSF, FSTF+AFO, | 5 | CP | ♂3 (60) | 9.7 yrs. ±3.5 | Not reported | Not reported | Not reported | Biomechanical (kinematic, kinetic, spatiotemporal) |
♀2 (40) | Range 5.6 to 12.6yrs. | |||||||||
Knittel and Staheli (1976) [41] | Not Stated | One group, SSF, Various forefoot and Rearfoot sole wedges, Torqheel, | 10 | In toeing | ♂4 (40) | 6.25 yrs. ±2.35 | Not reported | Not reported | Not reported | Biomechanical (kinematic) |
♀6 (60) | Range 3.5 to 10 yrs. | |||||||||
Wesdock & Edge (2003) [42] | 8 weeks | One group, SSF, SSF and AFO, FSTF+AFO | 11 | CP | ♂4 (36) | 7 yrs. ±2.7 | Not reported | Not reported | Not reported | Biomechanical (spatiotemporal) |
♀7 (64) | Range 4 to 13.5 yrs. | |||||||||
Subset of Group 1 SSF, SSF and AFO, FSTF+AFO | 4 | CP Initial standing balance ≥15 seconds | ♂3 (75) | 6.5 yrs. ±2 | Not reported | Not reported | Not reported | |||
♀1 (25) | Range 4.6 to 9.3 yrs. | |||||||||
Functional Instability | ||||||||||
Ramstrand et al (2008) [43] | 8 weeks | One Group FITF 8wk training program | 10 | CP + otherg | ♂6 (60) | 13.8 yrs. ±2.7 | 51.71 11.18 | 1.59 | Not Reported | Biomechanical (balance: static, dynamic) |
♀4 (40) | Range 10 to 17 yrs. | 0.11 | ||||||||
Functional Lift | ||||||||||
Eek et al (2017) | Within 1 day | Group 1 BF, SSF, FLTF | 10 | Spastic CP with LLD ≥1cm | ♂6 (60) | 10.9 yrs. Range 7.8 to 12.8 | 38.6 | 1.42, | Not Reported | Biomechanical (kinematic, spatiotemporal) |
♀4 (40) | Range 25.7-59.0 | Range 1.24-1.52 | ||||||||
Group 2 BF, SSF | 10 | Control typically developing | ♂5 (50) | 10.7yrs | 35.1 | 1.48 | ||||
♀5 (50) | Range 7.1 to 14 | Range 18.7-49 | Range 1.20-1.67 | |||||||
Zabjek et al (2001) [44] | Within 1 day | One Group, BF, FLTF | 46 | Idiopathic scoliosis | ♂9 (19.6) | 12yrs. ±2 | Not Reported | Not Reported | Not Reported | Skeletal Geometry (3D stereovideographic) |
♀37 (80.4) |
Study | Description provided of therapeutic footwear intervention (s) |
---|---|
Corrective Therapeutic Footwear | |
Chen et al (2015) [16] | Orthopaedic shoe with an orthopaedic insole and hard heel cup (CTF) |
Kanatli et al (2016) [12] | Custom made orthopaedic shoe, 0.5-0.9cm longitudinal arch support, 3-4mm heel wedges. (CTF) |
Wenger et al (1989) [37] | Orthopaedic shoe, steel shank, Thomas heel, long medial heel counter, navicular pad (CTF) |
Functional Therapeutic Footwear | |
Functional Stability | |
Abd Elkader et al (2013) [14] | Medical shoes same brand and model (brand/model not stated) with prefabricated arch insert (FSTF) |
Aboutorabi et al (2014) [11] | Custom made, High-top shoes, wide toe box, internal heel counter, arch inlay (FSTF) |
Bakker et al (1997) [38] | No details other than off the shelf orthopaedic footwear (FSTF) |
Basta et al (1977) [39] | High topped, Steel Shank, firm counter (FSTF) |
Jagadamma et al (2009) [40] | Custom made heel to forefoot wedged EVA sole adhesion, used alongside AFO. Wedges adjusted until shank to vertical angle reached 12°. (FSTF+AFO) |
Knittel and Staheli (1976) [41] | Low cut shoe with 9 various sole modifications, medial forefoot wedge only (FSTF 1), lateral forefoot wedge only (FSTF 2), medial forefoot and medial rearfoot wedge (FSTF 3), lateral forefoot and medial rearfoot wedge (FSTF 4), lateral forefoot and lateral rearfoot wedge (FSTF 5), medial rearfoot wedge only (FSTF 6), lateral rearfoot wedge only (FSTF 7), parallel torqheel (FSTF 8), circular torqheel (FSTF 9). |
Wesdock & Edge (2003) [42] | Custom made Styrofoam wedged sole adhesion, wedge = vertical distance of posterior inferior elevated heel of the unaltered shoe from the floor when subject with crouch gait stood as erect as possible. (FSTF+AFO) |
Functional Instability | |
Ramstrand et al (2008) [43] | Masai Barefoot Technologies, MBT unstable sole shoe. (FITF) |
Functional Lift | |
Eek et al (2017) [10] | 12 mm EVA sole adhesion divided into two parts heel and forefoot, (FLTF) |
Zabjek et al (2001) [44] | Various sole lift adhesion 5mm, 10mm,15mm, (FLTF) |
Outcome | Study | Condition | Group | Baseline Mean (SD ±/-) | Final Mean (SD ±/-) | Statistical Result (Significant values given in bold) |
---|---|---|---|---|---|---|
Corrective Therapeutic Footwear | ||||||
3D Laser scanning | ||||||
Bean shaped ratio | CTEV | Group 1 CTF and DB | N/A | 0.29 (0.27-0.30)a | One-way MANOVA: p=0.002 | |
Group 2 DB and Own footwear | N/A | 0.31 (0.29-0.33) a | Post hoc: | |||
Group 3 vs. 1 p<0.01 | ||||||
Group 3 FAS and CTF | N/A | 0.27 (0.25-0.28) a | Group 3 vs. 2 p<0.01 | | |||
Bimalleolar angle (°) | CTEV | Group 1 CTF and DB | N/A | 75.59 (73.98-77.21) a | One-way MANOVA: p=0.032 | |
Group 2 DB and Own footwear | N/A | 72.98 (69.03-6.92) a | Post hoc: | |||
Group 2 vs. 3 p<0.01 | | ||||||
Group 3 FAS and CTF | N/A | 77.55 (75.57-79.53) a | ||||
Radiographic (Anterior-Posterior view) | ||||||
Talo calcaneal angle (°) | Mobile pes planus | Group 1 CTF | 34d (22-53) b | 23d (12-37) b | Wilcoxon signed rank: | |
Group1 p=0.002; Group 2 p=0.003 | ||||||
Group 2 Own footwear | 33d (20-45) b | 30d (13-37) b | Mann Whitney U: | |||
Group 1 vs.2 p=0.19 | ||||||
Mobile pes planus | Group 1 CTF | 36.2 (1.2) c | 29.4 (0.74) c | One Way ANOVA: p>0.5 | ||
Group 2 SLF | 36.3 (0.99) c | 31.5 (1.2) c | ||||
Group 3 CTF with Helfet heel cup | 37.1 (0.84) c | 30 (0.77) c | ||||
Group 4 SLF with UCBL | 36.8 (0.97) c | 30.1 (0.82) c | ||||
Radiographic (Lateral view) | ||||||
Calcaneal pitch (°) | Mobile pes planus | Group 1 CTF | 12d (2-20) b | 15d (4-20) b | Wilcoxon signed rank: | |
Group 1 p=0.002; | ||||||
Group 2 p=0.001 | ||||||
Group 2 Own footwear | 10d (1-16) b | 14d (4-22) b | Mann Whitney U: | |||
Group 1 vs. 2 p=0.18 | ||||||
Talar 1st metatarsal angle (°) | Mobile pes planus | Group 1 CTF | 16d (7-29) b | 10d (0-26) b | Wilcoxon signed rank: | |
Group 1 p=0.001; | ||||||
Group 2 p=0.001 | ||||||
Group 2 Own footwear | 18.4d (6-35) b | 9.3d (0-34) b | Mann Whitney U: Group 1 vs. 2 p=0.72 | |||
Mobile pes planus | Group 1 CTF | 19.1 (0.75) c | 11.7 (0.84) c | One-way ANOVA: p>0.5 | ||
Group 2 SLF | 16.7 (0.87) c | 11.8 (0.91) c | ||||
Group 3 CTF with Helfet heel cup | 16.8 (0.76) c | 11.5 (0.67) c | ||||
Group 4 SLF with UCBL | 19.7 (0.83) c | 11.3 (0.98) c | ||||
Talo calcaneal angle (°) | Mobile pes planus | Group 1 CTF | 46d (27-56) b | 44d (32-57) b | Wilcoxon signed rank: | |
Group1 p=0.736; | ||||||
Group 2 p=0.113 | ||||||
Group 2 Own footwear | 46d (34-55) b | 43d (32-51) b | Mann Whitney U: | |||
Group 1 vs. 2 p=0.24 | ||||||
Talar horizontal angle (°) | Mobile pes planus | Group 1 CTF | 34d (16-49) b | 29d (19-42) b | Wilcoxon signed rank: | |
Group 1 p=0.003; | ||||||
Group 2 p=0.001 | ||||||
Group 2 Own footwear | 35d (21-52) b | 27d (21-44) b | Mann Whitney U: | |||
Group 1 vs. 2 p=0.09 | ||||||
Mobile pes planus | Group 1 CTF | 40.5 (0.70) c | 34 (0.66) c | One Way ANOVA: p>0.4 | ||
Group 2 SLF | 39.8 (0.71) c | 34.7 (0.73) c | ||||
Group 3 CTF with Helfet heel cup | 39.5 (0.6) c | 34.7 (0.61) c | ||||
Group 4 SLF with UCBL | 41.8 (0.78) c | 34.2 (0.84) c | ||||
Functional Stability Therapeutic Footwear | ||||||
Radiographic (Anterior-Posterior view) | ||||||
Talocalcaneal angle (°) | Symptomatic mobile pes planus | Group 1 Change from BF wearing FSTF | -4.2 | No Statistical test for significance performed | ||
Group 1 Change from FSTF wearing FSTF + CNP | -1 | |||||
Group2 Change from BF with FSTF | -3.8 | |||||
Group 2 Change from FSTF wearing FSTF+CNP | -1.5 | |||||
Group 3 -6 | No Data Reported | No Data Reported | ||||
Group 7 Change from BF wearing FSTF | -4.1 | |||||
Group 7 Change from FSTF wearing FSTF + CNP | -1.4 | |||||
Radiographic (Lateral view) | ||||||
Calcaneal pitch (°) | Symptomatic mobile pes planus | Group 1 Change from BF wearing FSTF | 1.8 | No Statistical test for significance performed | ||
Group 1 Change from FSTF wearing FSTF + CNP | 2.1 | |||||
Group2 Change from BF with FSTF | 1.8 | |||||
Group 2 Change from FSTF wearing FSTF+CNP | 2 | |||||
Group 3 -6 | No Data Reported | No Data Reported | ||||
Group 7 Change from BF wearing FSTF | 2.1 | |||||
Group 7 Change from FSTF wearing FSTF + CNP | 1.55 | |||||
Longitudinal arch angle (°) | Group 1 Change from BF wearing FSTF | -2.75 | No Statistical test for significance performed | |||
Group 1 Change from FSTF wearing FSTF + CNP | -0.9 | |||||
Group2 Change from BF with FSTF | -2.5 | |||||
Group 2 Change from FSTF wearing FSTF + CNP | -0.9 | |||||
Group 3 -6 | No Data Reported | No Data Reported | ||||
Group 7 Change from BF wearing FSTF | -2.6 | |||||
Group 7 Change from FSTF wearing FSTF+CNP | -1.2 | |||||
Talo calcaneal angle (°) | Group 1 Change from BF wearing FSTF | 0.9 | No Statistical test for significance performed | |||
Group 1 Change from FSTF wearing FSTF + CNP | -1.35 | |||||
Group2 Change from BF with FSTF | 0.7 | |||||
Group 2 Change from FSTF wearing FSTF + CNP | -1.25 | |||||
Group 3 -6 | No Data Reported | No Data Reported | ||||
Group 7 Change from BF wearing FSTF | 0.8 | |||||
Group 7 Change from FSTF wearing FSTF+CNP | -1.3 | |||||
Functional Lift Therapeutic Footwear | ||||||
3D stereovideographic | ||||||
Anteroposterior shift of sacral 1 (mm) | Idiopathic scoliosis | BF vs. FLTF | 12 (19) | 7 (5) | Paired t test: p>0.05 | |
Anteroposterior shift thoracic 1 (mm) | BF vs. FLTF | 32 (20) | 7 (7) | p<0.05 | ||
Anteroposterior shift shoulders/pelvis (mm) | BF vs. FLTF | 20 (18) | 6 (5) | p<0.05 | ||
Diff in height left-right tibia (mm) | BF vs. FLTF | -3 (5) | 11 (4) | p<0.05 | ||
Diff in height left-right trochanter (mm) | BF vs. FLTF | -10 (10) | 15 (6) | p<0.05 | ||
Kyphosis (%) | BF vs. FLTF | 7 (3) | 0.6 (0.6) | p>0.05 | ||
Lateral shift sacral 1 (mm) | BF vs. FLTF | 1 (10) | 9 (6) | p<0.05 | ||
Lateral shift shoulder/pelvis (mm) | BF vs. FLTF | 12 (10) | 4 (3) | p>0.05 | ||
Lateral shift thoracic 1 (mm) | BF vs. FLTF | 13 (15) | 9 (7) | p>0.05 | ||
Lordosis (%) | BF vs. FLTF | 4 (2) | 0.5 (0.5) | p>0.05 | ||
Pelvic rotation (°) | BF vs. FLTF | 0.4 (4) | 2 (2) | p>0.05 | ||
Pelvic tilt (°) | BF vs. FLTF | 3 (1) | 3 (1) | p<0.05 | ||
Rotation shoulder/pelvis (°) | BF vs. FLTF | 1 (4) | 1 (1) | p>0.05 | ||
Shoulder rotation (°) | BF vs. FLTF | 1 (4) | 2 (2) | p>0.05 | ||
Shoulder tilt (°) | BF vs. FLTF | 0.4 (2) | 0.8 (0.6) | p<0.05 | ||
Tilt shoulder/pelvis (°) | BF vs. FLTF | -2 (2) | 3 (2) | p<0.05 | ||
Vertical height of sacral 1 (mm) | BF vs. FLTF | 897 (84) | 5 (3) | p<0.05 | ||
Vertical height of thoracic 1 (mm) | BF vs. FLTF | 1279 (117) | 6 (3) | p<0.05 | ||
Version left iliac bone (°) | BF vs. FLTF | -11 (4) | 1 (1) | p<0.05 | ||
Version right iliac bone (°) | BF vs. FLTF | -10 (4) | 2 (1) | p<0.05 | ||
Diff in version right and left iliac (°) | BF vs. FLTF | -0.5 (2) | 2 (1) | p<0.05 |
Outcome | Study | Condition | Group | Baseline Mean (SD ±/-) | Final Mean (SD ±/-) | Statistical Result (Significant values given in bold) |
---|---|---|---|---|---|---|
Corrective Therapeutic Footwear | ||||||
Plantar pressure | ||||||
Average peak pressure (kPa): Lateral midfoot | CTEV | Group 1 CTF and DB | N/A | 62.21 (53.35-71.06) b | One-way MANOVA: p=0.005 | |
Group2 DB and Own footwear | N/A | 94.97 (66.38-123.59) b | Post hoc: | |||
Group 1 vs. Group 2 p<0.01 | ||||||
Group 3 FAS and CTF | N/A | 60.9 (49.26-72.54) b | Group 2 vs. Group 3 p<0.01 | |||
Maximum peak pressure (kPa): Hindfoot | Group 1 CTF and DB | N/A | 148.71 (135.49-161.94) b | One-way MANOVA: p<0.001 | ||
Group2 DB and Own footwear | N/A | 105.51 (85.73-125.29) b | Post hoc: | |||
Group 1 vs Group 2 p<0.01 | ||||||
Group 3 FAS and CTF | N/A | 164.05 (148.22-179.90) b | Group 2 vs. Group 3 p<0.001 | |||
Peak pressure ratio: Heel/forefoot | Group 1 CTF and DB | N/A | 0.72 (0.58-0.87) b | One-way MANOVA: | ||
p=0.009 | ||||||
Group2 DB and Own footwear | N/A | 0.44 (0.29-0.58) b | Post hoc | |||
Group 3 FAS and CTF | N/A | 0.73 (0.61-0.86) b | Group 1 vs. Group 2 p<0.01; | |||
Group 2 vs. Group 3 p<0.01 | ||||||
Peak pressure ratio: Heel/lateral midfoot | Group 1 CTF and DB | N/A | 1.45 (1.19-1.72) b | One-way MANOVA: | ||
p<0.001 | ||||||
Group2 DB and Own footwear | N/A | 0.77 (0.47-1.08) b | Post hoc: | |||
Group 3 FAS and CTF | N/A | 1.98 (1.68-2.29) b | Group 1 vs. Group2 p<0.01; | |||
Group 1 vs. Group 3 p<0.01; | ||||||
Group 2 vs. Group3 p<0.001 | ||||||
Functional Stability Therapeutic Footwear | ||||||
Kinematic | ||||||
Angle of gait (°) | In toeing | SSF | - 17.3 (11.9) | ANOVA: | ||
p<0.05 | ||||||
FSTF1 | - 18.3 (12.4) | Post hoc | ||||
FSTF2 | - 17.7 (13.9) | FSTF1 vs. SSF p<0.05 | ||||
FSTF3 | - 16.7 (12.7) | |||||
FSTF4 | - 17.1 (12.5) | FSTF7 vs. SSF p<0.05 | ||||
FSTF5 | - 16.7 (14.2) | |||||
FSTF6 | - 17.0 (14.3) | FSTF8 vs. SSF p<0.05 | ||||
FSTF7 | - 16.9 (12.4) | |||||
FSTF8 | - 15.6 (14.1) | FSTF9 vs. SSF p<0.05 | ||||
FSTF9 | - 10.7 (14.9) | |||||
Max. knee extension (°) stance | Cerebral palsy | AFO and SSF | - 2.6 (2.8) | Wilcoxon signed rank: p=0.04 | ||
FSTF+AFO | 3.7 (3.3) | |||||
Knee flexion (°) initial contact | AFO and SSF | 13.7 (8.4) | p=0.14 | |||
FSTF+AFO | 17.2 (5.1) | |||||
Max. knee flexion (°) stance | AFO and SSF | 19.7 (9.3) | p=0.06 | |||
FSTF+AFO | 25.2 (5.3) | |||||
Shank to vertical angle (SVA) (°) | AFO and SSF | 5.6 (3) | p=0.005 | |||
FSTF+AFO | 10.8 (1.8) | |||||
Kinetic | ||||||
Peak knee flexion moment (N m) stance | Cerebral palsy | AFO and SSF | 0.59 (0.31) | Wilcoxon signed rank: p=0.25 | ||
FSTF+AFO | 0.7 (0.32) | |||||
Peak Knee extension moment (N m) stance | AFO and SSF | - 0.44 (0.2) | p=0.14 | |||
FSTF+AFO | - 0.29 (0.24) | |||||
Spatiotemporal | ||||||
Base of support (cm) | Mobile pes planus | Group 1 BF | 11.80 (1.06) | Paired t test: | ||
Group 1 FSTF | 9.10 (1.31) | Group 1 p<0.05; | ||||
Group 2 p<0.05 | ||||||
Group 2 BF | 12.63 (1.96) | Independent t test | ||||
Group 2 FT | 9.20 (1.17) | BF p=0.12; | ||||
FSTF vs. FT p=0.86 | ||||||
Cadence (Steps/min) | Cerebral palsy | AFO and SSF | 122.5 (16.6) | Paired t test: | ||
FSTF+AFO | 122.3 (12.4) | p=0.97 | ||||
CoP displacement (mm) | Mobile pes planus | BF | 6.55 (6.40) | Repeated measures ANOVA: | ||
p=0.016 | ||||||
FSTF | 5.84 (6.15) | Post hoc: | ||||
SLS+FO | 5.87 (6.40) | FSTF vs. BF p<0.05 | ||||
Standing balance (s) | Cerebral palsy | Group1 SSF (after 4 weeks wear of solid AFO) | 11 (13) | Mixed model maximum likelihood estimate: p>0.05 | ||
Crouch gait | Group 1 SSF + AFO (after 4 weeks wear of solid AFO) | 18 (23) | ||||
Group 1 FSTF+AFO (after 4 weeks wear of solid AFO) | 50 (68) | |||||
Group 1 SSF (after 4 weeks wear of FSTF+AFO) | 14 (23) | |||||
Group 1 SSF + AFO (after 4 weeks wear of FSTF+AFO) | 11 (24) | |||||
Group 1 FSTF+AFO (after 4 weeks wear of FSTF+AFO) | 49 (70) | |||||
Difference in standing balance (s) | Cerebral palsy | Group 1 SSF vs. SSF+AFO (after 4 weeks wear of solid AFO) | (-6)-20 b | No Statistical test for significance performed | ||
Group1 SSF+AFO vs. FSTF+AFO (after 4 weeks wear of solid AFO) | (-2)-66b | |||||
Group1 SSF vs. FSTF+AFO (after 4 weeks wear of solid AFO) | 7 -73b | |||||
Group1 SSF vs. SSF+AFO (after 4 weeks wear of solid AFO) | (-19)-13b | |||||
Group 1 SSF+AFO vs. FSTF+AFO (after 4 weeks wear of solid AFO) | 3-73 b | |||||
Group1 SSF vs. FSTF+AFO (after 4 weeks wear of solid AFO) | 0-70 b | |||||
Cerebral palsy | SSF vs. SSF+AFO (after 4 weeks wear of solid AFO) | 14 (6) | after 4 weeks wear of solid AFO | |||
Subset of Group1 all participants who could stand ≥15s | SSF+AFO vs. FSTF+AFO (after 4 weeks wear of solid AFO) | 84 (41) | SSF vs. FSTF+AFO p<0.05; | |||
SSF vs. FSTF+AFO (after 4 weeks wear of solid AFO) | 98 (47) | SSF+AFO vs. FSTF+AFO p<0.05; | ||||
SSF vs. SSF+AFO (after 4 weeks wear of FSTF+AFO) | - 8 (7) | after 4 weeks wear of solid FSTF+AFO | ||||
SSF+AFO vs. FSTF+AFO (after 4 weeks wear of FSTF+AFO) | 101 (25) | SSF vs. FSTF+AFO p<0.05; | ||||
SSF vs. FSTF+AFO (after 4 weeks wear of FSTF+AFO) | 93 (33) | SSF+AFO vs. FSTF+AFO p<0.05 | ||||
(Sig based on 95% Confidence Interval of Group 1 differences in standing balance) | ||||||
Step length (cm) | Down’s Syndrome mobile pes planus | Group 1 BF | 26.53 (3.72) | Paired t test: | ||
Group1 FSTF | 30.83 (4.28) | Group 1 p<0.05 | ||||
Group 2 p<0.05 | ||||||
Group 2 BF | 25.63 (4.62) | Independent t test: | ||||
Group 2 FT | 30.73 (5.51) | BF Group 1 vs. 2 p=0.62; | ||||
FSTF vs. FT p=0.95 | ||||||
Mobile pes planus | BF | 37.99 (3.82) | Repeated measures ANOVA: p=0.478 | |||
FSTF | 38.85 (4.97) | |||||
SLS+FO | 39.05 (4.68) | |||||
Step symmetry (%) | Mobile pes planus | BF | -4.90 (4.66) | Repeated measures ANOVA: p=0.000 | ||
FSTF | -2.70 (25.54) | Post hoc | ||||
SLS+FO | 16.08 (31.25) | FSTF vs. SLS+FO p<0.05 | ||||
Step width (cm) | Mobile pes planus | BF | 8.87 (1.61) | Repeated measures ANOVA: p=0.170 | ||
FSTF | 8.91 (1.99) | |||||
SLS+FO | 9.41 (1.69) | |||||
Stride length (m) | Down’s Syndrome mobile pes planus | Group 1 BF | 0.448 (0.06) | Paired t test: | ||
Group 1 FSTF | 0.504 (0.064) | Group 1 p<0.05 | ||||
Group 2 p<0.05 | ||||||
Group 2 BF | 0.455 (0.071) | Independent t test: | ||||
Group 2 FT | 0.524 (0.078) | BF Group 1 vs. 2 p=0.82; | ||||
FSTF vs. FT p=0.44 | ||||||
Cerebral palsy | AFO and SSF | 1.08 (0.19) | Paired t test: p=0.54 | |||
FSTF+AFO | 1.06 (0.20) | |||||
Velocity (m/s) | Down’s Syndrome mobile pes planus | Group 1 BF | 0.674 (.059) | Paired t test: | ||
Group 1 FSTF | 0.775 (0.035) | Group 1 p<0.05 | ||||
Group 2 p<0.05 | ||||||
Group 2 BF | 0.672 (0.109) | Independent t test: | ||||
Group 2 FT | 0.762 (0.090) | BF Group 1 vs. 2 p=0.95; | ||||
FSTF vs. FT p=0.61 | ||||||
Mobile pes planus | BF | 0.727 (0.136) | Repeated measures ANOVA: p=0.000 | |||
FSTF | 0.847 (0.156) | Post hoc: | ||||
SLS+FO | 0.779 (0.128) | FSTF vs. BF p<0.05; | ||||
SLF +FO vs. BF p<0.05 | ||||||
Cerebral palsy | AFO and SSF | 1.08 (0.1) | Paired t test: p=0.80 | |||
FSTF+AFO | 1.07 (0.14) | |||||
Functional Instability Therapeutic Footwear | ||||||
Balance (Dynamic) | ||||||
Anterior posterior control (CoP) | Cerebral Palsy + mixed developmental disability | BF Medium (at 4 weeks) | 45.7 (25.5-66.5) b | Wilcoxon signed rank | ||
FITF Medium (at 4 weeks) | 51.44 (33.7-69.2) b | BF vs. FITF Medium at week 4 p<0.05 | ||||
Mediolateral control (CoP) | BF Slow (baseline) | 57.2 (47.0-67.2) b | Friedman ANOVA: | |||
BF Slow p<0.05 | ||||||
BF Medium (baseline) | 66.4 (52.6-80.1) b | Post hoc | ||||
BF Slow at week 8 vs. week 4 and baseline p<0.05 | ||||||
Wilcoxon signed rank | ||||||
BF Slow (at 4 weeks) | 69.2 (59.9-78.5) b | BF vs. FITF Slow at 8 weeks p<0.05; | ||||
BF Medium (at 4 weeks) | 75 (67.4-82.6) b | BF vs. FITF Medium at 4- and 8-weeks p<0.05 | ||||
FITF Slow (at 4 weeks) | 55.1 (36.3-73) b | |||||
FITF Medium (at 4 weeks) | 67 (54.3-79.2) b | |||||
BF Slow (at 8 weeks) | 74.89 (64.9-84.8) b | |||||
BF Medium (at 8 weeks) | 72.44 (55.1-89.9) b | |||||
FITF Slow (at 8 weeks) | 57.56 (40.3-74.8) b | |||||
FITF Medium (at 8 weeks) | 65.33 (44.5-86.2) b | |||||
Number of falls toes up condition | Subject 1,2,6,9,10 | 0 | Chi Square: | |||
Subject 3 | 2 | Between testing occasions p<0.05 | ||||
Subject 4 | 3 | |||||
Subjects 5,8 | 4 | |||||
Subject 7 | 10 | |||||
Subjects 1,5, 8 -10 (at 4 weeks) | 0 | |||||
Subjects 2, 6 (at 4 weeks) | Did not participate | |||||
Subjects 3 ,4 (at 4 weeks) | 1 | |||||
Subject 7 (at 4 weeks) | 2 | |||||
Subjects 1,2, 4 - 10 (at 8 weeks) | 0 | |||||
Subject 3 (at 8 weeks) | 1 | |||||
Functional Lift Therapeutic Footwear | ||||||
Kinematic | ||||||
Ankle dorsiflexion at initial contact (°) | Cerebral palsy | BF Long leg | -2.3d (7.9) e | Wilcoxon signed rank: | ||
BF Short leg | -9.2d (13.6) e | Comparison long to short | ||||
FLTF Long leg | 4.3d (9.1) e | BF p = 0.009; | ||||
FLTF Short leg | -2d (17) e | FLTF p= 0.017; | ||||
SSF Long leg | 3.5d (9.) e | SSF p=0.009 | ||||
SSF Short leg | -6.2d (11.3) e | |||||
Ankle dorsiflexion in stance (°) | BF Long leg | 11.9d (11.6) e | Comparison long to short | |||
BF Short leg | 6.5d (6.4) e | BF p = 0.22; | ||||
FLTF Long leg | 15.1d (4.9) e | FLTF p=0.241; | ||||
FLTF Short leg | 14.4d (8.6) e | SSF p=0.022 | ||||
SSF Long leg | 16.5d (2.8) e | |||||
SSF Short leg | 11.4d (10.7) e | |||||
Ankle dorsiflexion in swing (°) | BF Long leg | 3.7d (5.8) e | Comparison long to short | |||
BF Short leg | 3.2d (5.5) e | BF p = 0.007; | ||||
FLTF Long leg | 6.5d (10.9) e | FLTF p=0.037; | ||||
FLTF Short leg | 2.6d (9.3) e | SSF p=0.13 | ||||
SSF Long leg | 5.8d (7.8) e | |||||
SSF Short leg | 0.5d (10.7) e | |||||
Hip adduction in stance (°) | BF Long leg | 8.4d (6.4) e | Comparison long to short | |||
BF Short leg | 7.4d (4.4) e | BF p = 0.959; | ||||
FLTF Long leg | 6.6d (2.9) e | FLTF p=0.646; | ||||
FLTF Short leg | 9.3d (7.5) e | SSF p=0.646 | ||||
SSF Long leg | 7.0d (4.8) e | |||||
SSF Short leg | 6.3d (4.8) e | |||||
Hip extension in stance (°) | BF Long leg | 9.6d (6.2) e | Comparison long to short | |||
BF Short leg | 11.3d (3.7) e | BF p = 0.114 | ||||
FLTF Long leg | 12.8d (8) e | FLTF p=0.241 | ||||
FLTF Short leg | 12.3d (5.70e | SSF p=0.203 | ||||
SSF Long leg | 11.9d (7.3) e | |||||
SSF Short leg | 12.5d (5.7) e | |||||
Hip flexion at initial contact (°) | BF Long leg | 36.3d (9.1) e | Comparison long to short | |||
BF Short leg | 29.8d (5.1) e | BF p = 0.005; | ||||
FLTF Long leg | 34.9d (5.4) e | FLTF p=0.139; | ||||
FLTF Short leg | 34.1d (4.1) e | SSF p=0.005 | ||||
SSF Long leg | 36.3d (4.3) e | |||||
SSF Short leg | 30.5d (8.3) e | |||||
Hip flexion in swing (°) | BF Long leg | 37.3 (6.9) e | Comparison long to short | |||
BF Short leg | 33.0 (5.5) e | BF p = 0.009; | ||||
FLTF Long leg | 38.7 (7.3) e | FLTF p=0.139; | ||||
FLTF Short leg | 36.9 (6.1) e | SSF p=0.028 | ||||
SSF Long leg | 36.3 (7.5) e | |||||
SSF Short leg | 33.3 (6.4) e | |||||
Knee extension in stance (°) | BF Long leg | 7.0d (9.6) e | Comparison long to short | |||
BF Short leg | 4.8d (12.6) e | BF p = 0.007; | ||||
FLTF Long leg | 4.9d (10.2) e | FLTF p=0.028; | ||||
FLTF Short leg | 1.9d (10.9) e | SSF p=0.007 | ||||
SSF Long leg | 8.8d (10.6) | |||||
SSF Short leg | 1.6d (8.7) e | |||||
Knee flexion at initial contact (°) | BF Long leg | 13.4d (6.8) e | Comparison long to short | |||
BF Short leg | 11.9d (7.8) e | BF p = 0.508; | ||||
FLTF Long leg | 7.7d (7.5) e | FLTF p=0.114; | ||||
FLTF Short leg | 9.4d (6.7) e | SSF p=0.386; | ||||
SSF Long leg | 7.3d (11.5) e | |||||
SSF Short leg | 8.10d (7.5) e | |||||
Knee flexion in swing (°) | BF Long leg | 63.8d (5.0) e | Comparison long to short | |||
BF Short leg | 62.2d (12.7) e | BF p = 0.203; | ||||
FLTF Long leg | 64.2d (5.2) e | FLTF p=0.445; | ||||
FLTF Short leg | 60.8d (13.4) e | SSF p=0.093 | ||||
SSF Long leg | 65.6d (2.7) e | |||||
SSF Short leg | 62.5d (15.3) e | |||||
Spatiotemporal | ||||||
Cadence steps/min | Cerebral palsy | BF | 100.6d (17.8) e | Friedman ANOVA: p>0.05 | ||
FLTF | 98.4d (25.7) e | |||||
SSF | 99.3d (24.9) e | |||||
Stance phase % | BF Long leg | 61.1d (2.03) e | Wilcoxon signed rank: | |||
BF Short leg | 56.8d (4.0) e | Comparison long to short | ||||
FLTF Long leg | 60.8d (292) e | BF p = 0.022; | ||||
FLTF Short leg | 60.0d (4.16) e | FLTF p=0.241; | ||||
SSF Long leg | 62.5d (1.91) e | SSF p=0.005 | ||||
SSF Short leg | 58.9d (3.90) e | |||||
Stride length (m) | BF | 1.12d (0.13) e | Friedman ANOVA: p<0.05 | |||
FLTF | 1.24d (0.12) e | Post hoc: | ||||
SSF | 1.24d (0.12) e | BF vs. FLTF p<0.05; | ||||
BF vs. SSF p<0.05 | ||||||
Velocity (m/s) | BF | 1.18d (0.16) e | Friedman ANOVA: p<0.05 | |||
FLTF | 1.24d (0.12) e | Post hoc: | ||||
SSF | 1.21d (0.22) e | BF vs. FLTF p<0.05 |
Outcome | Study | Condition | Group | Baseline Mean (SD ±/-) | Finala Mean (SD +/-) |
---|---|---|---|---|---|
Functional Stability Therapeutic Footwear | |||||
Pain whilst using device | DMD | FSTF | N/A | 1.42 (0.53) | |
1=no pain | Own footwear | N/A | 1.02(0.51) | ||
KAFO | N/A | 3.0 (1.87) | |||
5=great deal of pain | SF | N/A | 2.33 (1.03) | ||
AFO | N/A | 2.20 (1.39) | |||
Reluctance to use device | FSTF | N/A | 2.28 (1.25) | ||
1=not reluctant | Own footwear | N/A | 1.29 (1.35) | ||
KAFO | N/A | 3.0 (1.58) | |||
5=great deal of reluctance | SF | N/A | 3.66 (1.21) | ||
AFO | N/A | 2.85 (1.53) |